These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 29899382

  • 1. Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2.
    Bittremieux M, La Rovere RM, Akl H, Martines C, Welkenhuyzen K, Dubron K, Baes M, Janssens A, Vandenberghe P, Laurenti L, Rietdorf K, Morciano G, Pinton P, Mikoshiba K, Bootman MD, Efremov DG, De Smedt H, Parys JB, Bultynck G.
    Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
    [Abstract] [Full Text] [Related]

  • 2. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H, Monaco G, La Rovere R, Welkenhuyzen K, Kiviluoto S, Vervliet T, Molgó J, Distelhorst CW, Missiaen L, Mikoshiba K, Parys JB, De Smedt H, Bultynck G.
    Cell Death Dis; 2013 May 16; 4(5):e632. PubMed ID: 23681227
    [Abstract] [Full Text] [Related]

  • 3. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H, La Rovere RM, Janssens A, Vandenberghe P, Parys JB, Bultynck G.
    Int J Dev Biol; 2015 May 16; 59(7-9):391-8. PubMed ID: 26260683
    [Abstract] [Full Text] [Related]

  • 4. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, Bultynck G.
    Biochim Biophys Acta; 2014 Oct 16; 1843(10):2240-52. PubMed ID: 24768714
    [Abstract] [Full Text] [Related]

  • 5. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca2+-dependent mPTP opening.
    Kerkhofs M, La Rovere R, Welkenhuysen K, Janssens A, Vandenberghe P, Madesh M, Parys JB, Bultynck G.
    Cell Calcium; 2021 Mar 16; 94():102333. PubMed ID: 33450506
    [Abstract] [Full Text] [Related]

  • 6. Extracellular and ER-stored Ca2+ contribute to BIRD-2-induced cell death in diffuse large B-cell lymphoma cells.
    Bittremieux M, La Rovere RM, Schuermans M, Luyten T, Mikoshiba K, Vangheluwe P, Parys JB, Bultynck G.
    Cell Death Discov; 2018 Mar 16; 4():101. PubMed ID: 30416758
    [Abstract] [Full Text] [Related]

  • 7. Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.
    Distelhorst CW.
    Biochim Biophys Acta Mol Cell Res; 2018 Nov 16; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [Abstract] [Full Text] [Related]

  • 8. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.
    Vervloessem T, Akl H, Tousseyn T, De Smedt H, Parys JB, Bultynck G.
    Oncotarget; 2017 Dec 19; 8(67):111656-111671. PubMed ID: 29340082
    [Abstract] [Full Text] [Related]

  • 9. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR, Zhong F, Chang MJ, Greenberg E, Choudhary Y, Smith MR, McColl KS, Pink J, Reu FJ, Matsuyama S, Distelhorst CW.
    Oncotarget; 2015 Sep 29; 6(29):27388-402. PubMed ID: 26317541
    [Abstract] [Full Text] [Related]

  • 10. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
    Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K, Matsuyama S, Herlitze S, Roderick HL, Bootman MD, Mignery GA, Parys JB, De Smedt H, Distelhorst CW.
    Mol Cell; 2008 Jul 25; 31(2):255-65. PubMed ID: 18657507
    [Abstract] [Full Text] [Related]

  • 11. Bcl-2 and IP3 compete for the ligand-binding domain of IP3Rs modulating Ca2+ signaling output.
    Ivanova H, Wagner LE, Tanimura A, Vandermarliere E, Luyten T, Welkenhuyzen K, Alzayady KJ, Wang L, Hamada K, Mikoshiba K, De Smedt H, Martens L, Yule DI, Parys JB, Bultynck G.
    Cell Mol Life Sci; 2019 Oct 25; 76(19):3843-3859. PubMed ID: 30989245
    [Abstract] [Full Text] [Related]

  • 12. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP3 Receptors.
    Distelhorst CW, Bootman MD.
    Cold Spring Harb Perspect Biol; 2019 Sep 03; 11(9):. PubMed ID: 31110129
    [Abstract] [Full Text] [Related]

  • 13. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G, Vervliet T, Akl H, Bultynck G.
    Cell Mol Life Sci; 2013 Apr 03; 70(7):1171-83. PubMed ID: 22955373
    [Abstract] [Full Text] [Related]

  • 14. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
    Zhong F, Harr MW, Bultynck G, Monaco G, Parys JB, De Smedt H, Rong YP, Molitoris JK, Lam M, Ryder C, Matsuyama S, Distelhorst CW.
    Blood; 2011 Mar 10; 117(10):2924-34. PubMed ID: 21193695
    [Abstract] [Full Text] [Related]

  • 15. Tracing the evolutionary history of Ca2+-signaling modulation by human Bcl-2: Insights from the Capsaspora owczarzaki IP3 receptor ortholog.
    Rosa N, Shabardina V, Ivanova H, Sebé-Pedrós A, Yule DI, Bultynck G.
    Biochim Biophys Acta Mol Cell Res; 2021 Nov 10; 1868(12):119121. PubMed ID: 34400171
    [Abstract] [Full Text] [Related]

  • 16. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP, Barr P, Yee VC, Distelhorst CW.
    Biochim Biophys Acta; 2009 Jun 10; 1793(6):971-8. PubMed ID: 19056433
    [Abstract] [Full Text] [Related]

  • 17. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
    Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H, Mignery GA, Roderick HL, Bootman MD, Distelhorst CW.
    Proc Natl Acad Sci U S A; 2009 Aug 25; 106(34):14397-402. PubMed ID: 19706527
    [Abstract] [Full Text] [Related]

  • 18. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
    Vervliet T, Parys JB, Bultynck G.
    Biochem Soc Trans; 2015 Jun 25; 43(3):396-404. PubMed ID: 26009182
    [Abstract] [Full Text] [Related]

  • 19. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
    Ivanova H, Ritaine A, Wagner L, Luyten T, Shapovalov G, Welkenhuyzen K, Seitaj B, Monaco G, De Smedt H, Prevarskaya N, Yule DI, Parys JB, Bultynck G.
    Oncotarget; 2016 Aug 23; 7(34):55704-55720. PubMed ID: 27494888
    [Abstract] [Full Text] [Related]

  • 20. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.
    Greenberg EF, McColl KS, Zhong F, Wildey G, Dowlati A, Distelhorst CW.
    Cell Death Dis; 2015 Dec 31; 6(12):e2034. PubMed ID: 26720343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.